Skip to content
Nonprofiteer
← GLOBAL HEALTH SOLUTIONS INC

Form 990 for tax year 2023

Filed by GLOBAL HEALTH SOLUTIONS INC.

Totals

Total revenue
$511,468,181
Total expenses
$511,468,181
Contributions and grants received
$511,468,181
Grants paid
$511,468,181
Program service revenue
$0
Investment income
$0
Other revenue
$0
Total assets, end of year
$0
Total liabilities, end of year
$0
Net assets or fund balances, end of year
$0
Program services expenses (Part IX)
$511,468,181
Management and general expenses
$0
Fundraising expenses
$0
Program service expenses (Part III)
$511,468,181

Program services were 100.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1a · Federated campaigns

    $0

  • 1b · Membership dues

    $0

  • 1c · Fundraising events

    $0

  • 1d · Related organizations

    $0

  • 1e · Government grants (contributions)

    $0

  • 1f · All other contributions, gifts and grants

    $511,468,181

  • 1g · Noncash contributions included above

    $0

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 7c · Gain or loss

    securities $0 · other assets $0

  • 8a · Fundraising events: contributions included on line 1c

    $0

  • 11e · Other revenue, total

    $0

Functional expenses

Part IX, the statement of functional expenses.

  • 3 · Grants to foreign organizations and individuals

    total $511,468,181 · program services $511,468,181

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $0 · end of year $0

  • 2 · Savings and temporary cash investments

    beginning of year $0 · end of year $0

  • 3 · Pledges and grants receivable

    beginning of year $0 · end of year $0

  • 4 · Accounts receivable

    beginning of year $0 · end of year $0

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 7 · Other notes and loans receivable

    beginning of year $0 · end of year $0

  • 8 · Inventories for sale or use

    beginning of year $0 · end of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $0 · end of year $0

  • 11 · Investments: publicly traded securities

    beginning of year $0 · end of year $0

  • 12 · Investments: other securities

    beginning of year $0 · end of year $0

  • 13 · Investments: program-related

    beginning of year $0 · end of year $0

  • 14 · Intangible assets

    beginning of year $0 · end of year $0

  • 15 · Other assets

    beginning of year $0 · end of year $0

  • 17 · Accounts payable and accrued expenses

    beginning of year $0 · end of year $0

  • 18 · Grants payable

    beginning of year $0 · end of year $0

  • 19 · Deferred revenue

    beginning of year $0 · end of year $0

  • 20 · Tax-exempt bond liabilities

    beginning of year $0 · end of year $0

  • 21 · Escrow or custodial account liability

    beginning of year $0 · end of year $0

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 23 · Secured mortgages and notes payable

    beginning of year $0 · end of year $0

  • 24 · Unsecured notes and loans payable

    beginning of year $0 · end of year $0

  • 25 · Other liabilities

    beginning of year $0

  • 27 · Net assets without donor restrictions

    beginning of year $0 · end of year $0

  • 28 · Net assets with donor restrictions

    beginning of year $0 · end of year $0

Mission and programs · 2023

Mission

As a supporting organization, support the global health efforts of The Task Force for Global Health, Inc. by principally receiving donated phamaceuticals and coordinating the shipment to designated countries for the treatment of blinding trachoma, river blindness and vaccine preventable diseases.

Activities or mission (Part I)

As a supporting organization, provide support to the global health initiatives of The Task Force for Global Health,Inc.

  • The International Trachoma Initiative (ITI) works tirelessly for a world free from trachoma. ITI contributes to eliminating trachoma as a public health threat by stewarding Pfizer's donation of azithromycin to treat and prevent the condition; building and strengthening partnerships to accelerate progress; and developing innovative tools to share data. Between September 2023 and August 2024, ITI organized just-in-time shipments of 33.3 million treatments for trachoma to be distributed at MDAs in 15 countries. As of August 2024, ITI has shipped more than 1.073 billion treatments to trachoma-endemic countries since the program's inception in 1999. ITI continued its data management support for Tropical Data, a free mobile phone-based service to support trachoma programs as they conduct prevalence surveys, providing them with robust data for decision-making on where antibiotic treatments are needed and where they can be stopped. Since its inception in February 2016, Tropical Data has supported over 3,823 surveys across 52 countries. As a key player in the global trachoma community, there have been tremendous achievements in reducing the population at risk of blindness from trachoma from an estimated 1.2 billion people in 2000 to 103.2 million in April 2024 according to the World Health Organization's (WHO) Weekly Epidemiological Record (WER). ITI will continue to work smarter so that the dream of a trachoma-free world becomes a reality.

    Expenses $458,632,706 · Revenue $458,632,706

  • Mectizan Donation Program Accomplishments In 2024, 406.1 million Mectizan treatments were approved for mass drug administration (MDA) for onchocerciasis and lymphatic filariasis (LF) elimination in 44 countries and territories. The breakdown of treatments approved is as follows: (a) 274.1 million for onchocerciasis only including 63 million treatments approved to implement a second round of treatment in 9 countries (Burkina Faso, DRC, Ethiopia, Ghana, Malawi, Nigeria, Tanzania, Togo, and Uganda). (b) 36.2 million for onchocerciasis & LF co-endemic communities. (c) 95.7 million for LF only, of which 52.8 million were approved for 14 countries implementing triple therapy with ivermectin, DEC, and albendazole (IDA). By the end of 2024, cumulatively, the number of Mectizan 3mg tablets shipped since the inception of the program reached 13.9 billion or 4.94 billion treatments. The 5 billionth treatment shipped will be reached in early 2025, a very exciting milestone that the Mectizan Donation Program (MDP) will celebrate with Merck & Co., Inc. and other partners working to eliminate these diseases. Timor Leste was validated by WHO for achieving the elimination of LF as a public health problem, the first country to achieve elimination using triple therapy with the WHO-recommended triple therapy strategy: ivermectin, DEC and albendazole (IDA). A press release was issued by MDP to congratulate the country. MDP supported WHO-HQ to prepare a request to be submitted to Merck for Mectizan donation to extend the donation of Mectizan for - triple therapy - or IDA (ivermectin, diethylcarbamazine, and albendazole. The application was submitted to Merck in November 2024 for consideration. MDP also supported WHO, country partners, and others in identifying challenges and creating solutions to ensure onchocerciasis and lymphatic filariasis remain on track to meet the goals established in the WHO 2021-2030 Road Map. A robust communications and advocacy plan including an annual report, social media, video production, and e-newsletter was implemented to share progress and relevant developments with partners. Our film - Eliminating Disease with Mectizan - produced in 2023 (renamed - The Pill That's Changed Millions of Lives) was entered by the producer in the 2024 Smiley Charity Awards, a high-profile award in the UK for non-profit causes. The film was selected as a finalist in the - Corporate Cause - and SDG 3 categories. The film did not win the award; however, this increased visibility for the donation of Mectizan and efforts to eliminate onchocerciasis and lymphatic filariasis.

    Expenses $52,835,475 · Revenue $52,835,475

As filed on the 2023 return.

Listed in Part VII

  • Patrick O'Carroll

    Chairman

    Total calculated
    $411,644
    From this org
    $0
    From related orgs
    $411,644
    Other
    $0
    Hours/week
    1 + 39 related

    Schedule J breakdown matched by us

    Base
    $0 + $380,636 related
    Bonus
    $0
    Other
    $0
    Deferred
    $0 + $29,700 related
    Nontaxable benefits
    $0 + $1,308 related
    Filer's total
    $0 + $411,644 related
  • Mark McKinlay

    Officer

    Total calculated
    $387,309
    From this org
    $0
    From related orgs
    $387,309
    Other
    $0
    Hours/week
    1 + 39 related

    Schedule J breakdown matched by us

    Base
    $0 + $316,424 related
    Bonus
    $0
    Other
    $0
    Deferred
    $0 + $28,960 related
    Nontaxable benefits
    $0 + $41,925 related
    Filer's total
    $0 + $387,309 related
  • William P Nichols

    Officer

    Total calculated
    $339,114
    From this org
    $0
    From related orgs
    $339,114
    Other
    $0
    Hours/week
    1 + 39 related

    Schedule J breakdown matched by us

    Base
    $0 + $310,032 related
    Bonus
    $0
    Other
    $0
    Deferred
    $0 + $27,903 related
    Nontaxable benefits
    $0 + $1,179 related
    Filer's total
    $0 + $339,114 related
  • Daniel N Martins

    Secretary

    Total calculated
    $253,744
    From this org
    $0
    From related orgs
    $253,744
    Other
    $0
    Hours/week
    1 + 39 related

    Schedule J breakdown matched by us

    Base
    $0 + $182,089 related
    Bonus
    $0 + $9,194 related
    Other
    $0
    Deferred
    $0 + $16,825 related
    Nontaxable benefits
    $0 + $45,636 related
    Filer's total
    $0 + $253,744 related
  • Ellen Wild

    Treasurer

    Total calculated
    $227,921
    From this org
    $0
    From related orgs
    $227,921
    Other
    $0
    Hours/week
    1 + 39 related

    Schedule J breakdown matched by us

    Base
    $0 + $201,573 related
    Bonus
    $0 + $7,000 related
    Other
    $0
    Deferred
    $0 + $18,274 related
    Nontaxable benefits
    $0 + $1,074 related
    Filer's total
    $0 + $227,921 related

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

None.

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

Schedule J, Part I, Line 3
The organization does not have employees but has officers who are paid by the related organization

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$511,468,181

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
East Asia and the Pacific 0 0 Program Services Donation of zithromax drug for the treatment of blinding trachoma $5,403,353
Middle East and North Africa 0 0 Program Services Donation of zithromax drug for the treatment of blinding trachoma. $11,474,201
Sub-Saharan Africa 0 0 Program Services Donation of zithromax drug for the treatment of blinding trachoma. $441,755,152
East Asia and the Pacific 0 0 Program Services Donation of mectizan drug for the treatment of lymphatic filariasis. $2,663,535
South America 0 0 Program Services Donation of mectizan drug for the treatment of lymphatic filariasis. $384,405
South Asia 0 0 Program Services Donation of mectizan drug for the treatment of lymphatic filariasis. $25,009,845
Sub-Saharan Africa 0 0 Program Services Donation of mectizan drug for the treatment of lymphatic filariasis. $24,683,190
Central America and the Caribbean 0 0 Program Services Donation of mectizan drug for the treatment of lymphatic filariasis. $94,500

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
Central America and the Caribbean $0 0 $94,500 Mectizan drug Lower of market or donor's cost.
East Asia and the Pacific $0 N/A $8,066,888 Drug donation - mectizan and zithromax Lower of market or donor's costs
Middle East and North Africa $0 N/A $11,474,201 Donated drugs - zithromax Lower of market or donor's cost
South America $0 N/A $384,405 Drug donation - Mectizan Lower of market or donor's cost
South Asia $0 N/A $25,009,845 Drug donation - Mectizan Lower of market or donor's cost
Sub-Saharan Africa $0 N/A $466,438,342 Drug donation - mectizan and zithromax Lower of market or donor's cost
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
34
Other grantees (Part II line 3)
0
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
Yes

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

Provenance

Return type
form_990
Tax year
2023
Filed
30 April 2025
IRS schema version
2023v6.0
Source object
202511569349301426

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.